Comparative Pharmacology
Head-to-head clinical analysis: KANUMA versus LUMIZYME.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KANUMA versus LUMIZYME.
KANUMA vs LUMIZYME
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Recombinant human lysosomal acid lipase (LAL) that catalyzes the hydrolysis of cholesteryl esters and triglycerides in lysosomes.
Alglucosidase alfa is a recombinant form of human acid alpha-glucosidase (GAA), which hydrolyzes lysosomal glycogen. It provides exogenous enzyme to reduce accumulation of glycogen in lysosomes.
1 mg/kg intravenously over 4 hours once weekly.
5 mg/kg administered intravenously once every 2 weeks.
None Documented
None Documented
Terminal elimination half-life: approximately 2–5 hours (range 1.5–7.5 hours) in patients with LAL deficiency. Clinical context: half-life supports weekly intravenous dosing.
Terminal half-life: 1.1–3.5 hours (mean 2.2 hours) after IV infusion; due to rapid uptake into lysosomes, shorter than many enzymes.
Primarily cleared via receptor-mediated endocytosis and lysosomal degradation; negligible renal or biliary/fecal elimination of active drug. <1% excreted unchanged in urine.
Eliminated via reticuloendothelial system; no significant renal or biliary excretion. <5% recovered unchanged in urine.
Category C
Category C
Enzyme Replacement Therapy
Enzyme Replacement Therapy